GILEAD SCIENCES INC (NASDAQ: GILD)

GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

最近更新时间: 5天之前, 12:27AM

123.91

-0.42 (-0.34%)

加入群组

前收盘价格	124.33
收盘价格	124.40
成交量	5,109,934
平均成交量 (3个月)	7,372,319
市值	153,748,389,888

市盈率 (P/E TTM)	19.24
预期市盈率 (P/E Forward)	14.47
价格/销量 (P/S)	5.51
股市价格/股市净资产 (P/B)	7.32

52周波幅	88.57 (-28%) — 128.70 (3%)
股息率 (DY TTM)	2.55%

市场趋势

		短期	中期
行业	Drug Manufacturers - General (US)	看涨	看跌
	Drug Manufacturers - General (全球的)	看涨	看跌
股票	Gilead Sciences, Inc.	看涨	看涨

AIStockmoo 评分

0.3

分析师共识	1.5
内部交易活动	-2.5
价格波动	-0.5
技术平均移动指标	2.5
技术振荡指标	0.5
平均	0.30

相关股票

股票	市值	DY	P/E（TTM）	P/B
GILD	154 B	2.55%	19.24	7.32
AMGN	182 B	2.82%	26.13	19.34
AZN	282 B	1.72%	30.18	6.09
SNY	121 B	4.47%	16.24	1.41
GRFS	7 B	1.96%	14.05	1.00
BIIB	27 B	-	16.61	1.42

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
部门	Healthcare
行业	Drug Manufacturers - General
投资方式	Large Value
内部持股比例	0.10%
机构持股比例	89.79%

52周波幅	88.57 (-28%) — 128.70 (3%)
目标价格波幅	105.00 (-15%) — 150.00 (21%)
高	150.00 (JP Morgan, 21.06%)	购买
中	140.00 (12.99%)
低	105.00 (RBC Capital, -15.26%)	保留
平均值	135.00 (8.95%)
总计	8 购买, 1 保留
平均价格@调整类型	121.54

公司	日期	目标价格	调整类型	价格@调整类型
Truist Securities	24 Nov 2025	140.00 (12.99%)	购买	125.27
Truist Securities	03 Nov 2025	145.00 (17.02%)	购买	122.05
Needham	13 Nov 2025	140.00 (12.99%)	购买	125.20
Needham	31 Oct 2025	133.00 (7.34%)	购买	119.79
Scotiabank	13 Nov 2025	140.00 (12.99%)	购买	125.20
Cantor Fitzgerald	31 Oct 2025	135.00 (8.95%)	购买	119.79
JP Morgan	31 Oct 2025	150.00 (21.06%)	购买	119.79
JP Morgan	16 Sep 2025	145.00 (17.02%)	购买	110.86
RBC Capital	31 Oct 2025	105.00 (-15.26%)	保留	119.79
Wells Fargo	31 Oct 2025	145.00 (17.02%)	购买	119.79
TD Cowen	23 Oct 2025	125.00 (0.88%)	购买	120.74
Citigroup	08 Oct 2025	135.00 (8.95%)	购买	118.25
显示更多

名称	平均购买 ($)	平均卖出 ($)	总净额	总净值 ($)
BLUESTONE JEFFREY	-	125.84	-5,000	-629,200
KRAMER KELLY A.	-	126.68	-5,611	-710,774
O'DAY DANIEL PATRICK	-	125.84	-10,000	-1,258,400
累积净数量				-20,611
累积净值 ($)				-2,598,374
累积平均购买 ($)				-
累积平均卖出 ($)				126.26

名称	持有人	日期	类型	数量	价格	价值 ($)
O'DAY DANIEL PATRICK	职员	28 Nov 2025	自动卖出 (-)	10,000	125.84	1,258,400
KRAMER KELLY A.	董事	28 Nov 2025	自动卖出 (-)	2,805	125.84	352,981
KRAMER KELLY A.	董事	28 Nov 2025	执行期权	2,805	-	-
BLUESTONE JEFFREY	董事	28 Nov 2025	卖 (-)	5,000	125.84	629,200
BLUESTONE JEFFREY	董事	28 Nov 2025	执行期权	5,000	-	-
KRAMER KELLY A.	董事	26 Nov 2025	自动卖出 (-)	2,806	127.51	357,793
KRAMER KELLY A.	董事	26 Nov 2025	执行期权	2,806	-	-

日期	类型	细节
06 Dec 2025	公告	Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
06 Dec 2025	公告	Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
24 Nov 2025	公告	Gilead Foundation Commits Over $3 Million to Address Food Insecurity
20 Nov 2025	公告	Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
18 Nov 2025	公告	Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
13 Nov 2025	公告	Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
07 Nov 2025	公告	Gilead Provides Update on Phase 3 ASCENT-07 Study
07 Nov 2025	公告	Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
04 Nov 2025	公告	Gilead Sciences to Present at Upcoming Investor Conferences
03 Nov 2025	公告	Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
31 Oct 2025	公告	Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
30 Oct 2025	公告	Gilead Sciences Announces Third Quarter 2025 Financial Results
23 Oct 2025	公告	Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
19 Oct 2025	公告	Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
19 Oct 2025	公告	Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
15 Oct 2025	公告	Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
13 Oct 2025	公告	Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
09 Oct 2025	公告	Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
25 Sep 2025	公告	Gilead Foundation Grants $6.5 Million in Commitment to STEM Education
显示更多

股息率 (DY TTM)	2.55%
5年平均股息收益率	3.80%
股息支付比率	65.13%
预计下次股息支付	Mar 2026

除息日	公告日期	支付日期	详情
15 Dec 2025	28 Oct 2025	30 Dec 2025	0.79 现金
15 Sep 2025	29 Jul 2025	29 Sep 2025	0.79 现金
13 Jun 2025	22 Apr 2025	27 Jun 2025	0.79 现金
14 Mar 2025	05 Feb 2025	28 Mar 2025	0.79 现金
13 Dec 2024	30 Oct 2024	30 Dec 2024	0.77 现金
13 Sep 2024	30 Jul 2024	27 Sep 2024	0.77 现金
14 Jun 2024	23 Apr 2024	27 Jun 2024	0.77 现金
14 Mar 2024	01 Feb 2024	28 Mar 2024	0.77 现金
14 Dec 2023	01 Nov 2023	28 Dec 2023	0.75 现金
14 Sep 2023	25 Jul 2023	28 Sep 2023	0.75 现金
14 Jun 2023	25 Apr 2023	29 Jun 2023	0.75 现金
14 Mar 2023	25 Jan 2023	30 Mar 2023	0.75 现金
14 Dec 2022	25 Oct 2022	29 Dec 2022	0.73 现金
14 Sep 2022	25 Jul 2022	29 Sep 2022	0.73 现金
14 Jun 2022	27 Apr 2022	29 Jun 2022	0.73 现金
14 Mar 2022	28 Jan 2022	30 Mar 2022	0.73 现金
14 Dec 2021	26 Oct 2021	30 Dec 2021	0.71 现金
14 Sep 2021	26 Jul 2021	29 Sep 2021	0.71 现金
14 Jun 2021	27 Apr 2021	29 Jun 2021	0.71 现金
12 Mar 2021	02 Feb 2021	30 Mar 2021	0.71 现金
14 Dec 2020	26 Oct 2020	30 Dec 2020	0.68 现金
14 Sep 2020	29 Jul 2020	29 Sep 2020	0.68 现金
11 Jun 2020	29 Apr 2020	29 Jun 2020	0.68 现金
12 Mar 2020	03 Feb 2020	30 Mar 2020	0.68 现金
12 Dec 2019	23 Oct 2019	30 Dec 2019	0.63 现金
12 Sep 2019	29 Jul 2019	27 Sep 2019	0.63 现金
13 Jun 2019	01 May 2019	27 Jun 2019	0.63 现金
14 Mar 2019	01 Feb 2019	28 Mar 2019	0.63 现金
13 Dec 2018	24 Oct 2018	28 Dec 2018	0.57 现金
13 Sep 2018	24 Jul 2018	27 Sep 2018	0.57 现金
14 Jun 2018	30 Apr 2018	28 Jun 2018	0.57 现金
15 Mar 2018	05 Feb 2018	29 Mar 2018	0.57 现金
14 Dec 2017	25 Oct 2017	28 Dec 2017	0.52 现金
14 Sep 2017	25 Jul 2017	28 Sep 2017	0.52 现金
14 Jun 2017	01 May 2017	29 Jun 2017	0.52 现金
14 Mar 2017	06 Feb 2017	30 Mar 2017	0.52 现金
13 Dec 2016	31 Oct 2016	29 Dec 2016	0.47 现金
14 Sep 2016	22 Jul 2016	29 Sep 2016	0.47 现金
14 Jun 2016	27 Apr 2016	29 Jun 2016	0.47 现金
14 Mar 2016	02 Feb 2016	30 Mar 2016	0.43 现金
14 Dec 2015	26 Oct 2015	30 Dec 2015	0.43 现金
14 Sep 2015	23 Jul 2015	29 Sep 2015	0.43 现金
12 Jun 2015	24 Apr 2015	29 Jun 2015	0.43 现金
显示更多

每年股息收益率

年份	每年总股息 ($)	频率/年份	收益率 %
2025	3.16	4	2.55
2024	3.08	4	3.33
2023	3.00	4	3.70
2022	2.92	4	3.40
2021	2.84	4	3.91
2020	2.72	4	4.67
2019	2.52	4	3.88
2018	2.28	4	3.65
2017	2.08	4	2.90
2016	1.84	4	2.57
2015	1.29	3	1.28
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2025	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

营业毛利率	20.76%
营业利益率 (TTM)	38.49%
稀释每股收益 (EPS TTM)	4.76
季度收入增长率 (YOY)	-0.30%
季度盈利增长率 (YOY)	24.80%

总债务/股东权益 (D/E MRQ)	130.79%
流动比率 (MRQ)	1.37
营业现金流 (OCF TTM)	10.37 B
杠杆自由现金流 (LFCF TTM)	9.99 B

资产报酬率 (ROA TTM)	12.14%
股东权益报酬率 (ROE TTM)	32.65%

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)